CTLA4 and melanoma: In a recent randomized control trial for untreated advanced melanoma, dual CTLA-4 and PD-1 blockade provided an improved ORR (58%) compared to monotherapy CTLA-4 (19%) and monotherapy PD-1 (44%).57